Tilray Brands (NASDAQ:TLRY) Shares Up 3.6% – Here’s What Happened

Posted by Stanley Muller on Aug 21st, 2026

Shares of Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report) traded up 3.6% during mid-day trading on Friday . The company traded as high as $4.94 and last traded at $4.84. Approximately 4,255,482 shares were traded during trading, a decline of 1% from the average daily volume of 4,297,825 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on TLRY shares. Wall Street Zen cut Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. TD Securities upgraded Tilray Brands to a “strong-buy” rating in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Tilray Brands in a research note on Friday, August 7th. Finally, TD Cowen cut their price target on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Read Our Latest Report on TLRY

Tilray Brands Stock Up 3.6%

The company has a quick ratio of 1.37, a current ratio of 2.21 and a debt-to-equity ratio of 0.22. The stock has a market cap of $659.23 million, a P/E ratio of -4.48 and a beta of 1.90. The company’s 50 day moving average price is $4.48 and its two-hundred day moving average price is $5.82.

Tilray Brands (NASDAQ:TLRY – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.42). The firm had revenue of $281.71 million during the quarter, compared to the consensus estimate of $246.30 million. Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%. As a group, research analysts expect that Tilray Brands, Inc. will post -0.42 earnings per share for the current year.

Insider Buying and Selling at Tilray Brands

In other news, CFO Carl A. Merton purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average price of $4.62 per share, with a total value of $46,200.00. Following the transaction, the chief financial officer owned 139,753 shares of the company’s stock, valued at $645,658.86. This represents a 7.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders acquired 15,000 shares of company stock valued at $69,225. 0.84% of the stock is currently owned by corporate insiders.

Institutional Trading of Tilray Brands

Institutional investors and hedge funds have recently made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new stake in Tilray Brands in the fourth quarter worth about $38,000. Cerity Partners LLC increased its position in Tilray Brands by 98.5% during the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after purchasing an additional 45,929 shares during the period. Marex Group plc purchased a new position in Tilray Brands during the 2nd quarter valued at about $40,000. Hilton Capital Management LLC purchased a new position in Tilray Brands during the 2nd quarter valued at about $41,000. Finally, Deutsche Bank AG bought a new stake in shares of Tilray Brands in the 2nd quarter valued at about $44,000. 9.35% of the stock is currently owned by institutional investors.

Tilray Brands Company Profile

(Get Free Report)

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.